Interpace Diagnostics Group (NASDAQ:IDXG)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $3.00 price target on the business services provider’s stock. HC Wainwright’s price objective would indicate a potential upside of 96.08% from the stock’s current price.
The analysts wrote, “Our price target is derived from a market value of the firm at $115M, which includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory- developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate.””
IDXG has been the subject of a number of other reports. Maxim Group set a $3.00 price target on Interpace Diagnostics Group and gave the company a “buy” rating in a research note on Thursday, July 19th. ValuEngine raised Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. Dawson James assumed coverage on Interpace Diagnostics Group in a research note on Wednesday, October 17th. They set a “buy” rating and a $4.00 price target for the company. Finally, Zacks Investment Research raised Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a research note on Wednesday, July 18th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Interpace Diagnostics Group currently has a consensus rating of “Buy” and a consensus price target of $3.17.
Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Thursday, August 9th. The business services provider reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The firm had revenue of $5.50 million during the quarter, compared to analyst estimates of $4.80 million. Interpace Diagnostics Group had a negative return on equity of 34.58% and a negative net margin of 71.14%. On average, equities research analysts predict that Interpace Diagnostics Group will post -0.31 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $194,000. Essex Investment Management Co. LLC acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $465,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Interpace Diagnostics Group during the 3rd quarter valued at $983,000. Institutional investors own 15.59% of the company’s stock.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.